Skip to main content

Day: December 14, 2025

Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome

Written by Customer Service on . Posted in Public Companies.

– Company to host live webcast and conference call Monday, December 15, 2025 at 8:00 am ET – EMERYVILLE, Calif., Dec. 14, 2025 (GLOBE NEWSWIRE) — Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced it will host a live webcast and conference call on Monday, December 15, 2025 at 8:00 am ET to review topline results from the registrational Phase 2 KYSA-8 clinical trial evaluating KYV-101 in stiff person syndrome (SPS). Conference Call Details Participants will need to register at the below-noted URL in order to listen and participate in the call. Once registered, participants will receive a dial-in phone number and unique PIN number which will be needed to join the call. The call can also be accessed via live webcast....

Continue reading

EDF: Update on the Flamanville EPR: the reactor has reached 100% of nuclear thermal power

Written by Customer Service on . Posted in Public Companies.

 Update on the Flamanville EPR: the reactor has reached 100% of nuclear thermal power 14 December 2025 marks a major milestone : the Flamanville 3 reactor reached 100% nuclear thermal power at 11:37am and generated 1,669MW of gross electrical power*. The ramp-up to 100% nuclear thermal power follows the approval by the French nuclear safety and radiation protection authority (ASNR) on 12 December 2025, to go beyond the 80% threshold. Reaching the 100% mark for the first time enables testing of equipment at full power, taking of measurements and verifying that everything is functioning properly. Over the coming weeks, and as part of the start-up program, the power of the reactor will vary to continue testing at different power levels and an operation will be carried out on an internal electrical substation. This milestone reflects the...

Continue reading

InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial

Written by Customer Service on . Posted in Public Companies.

BEIJING, Dec. 14, 2025 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the phase IIb clinical study of novel BTK inhibitor orelabrutinib has met the primary endpoint in patients with systemic lupus erythematosus (SLE). InnoCare has also received approval from the Center for Drug Evaluation (CDE) to conduct a phase III registrational clinical trial. Orelabrutinib demonstrated outstanding efficacy and well-tolerated safety profile in patients with SLE who had received 48 weeks of treatment in the phase IIb study. A total of 187 patients were enrolled and randomized (1:1:1) into three groups: orelabrutinib 75 mg once-daily (QD), orelabrutinib 50 mg QD, and placebo. The primary endpoint of this study...

Continue reading

Pollock Company Acquires ATG Communications, Strengthening Local Technology Infrastructure

Written by Customer Service on . Posted in Mergers And Acquisitions.

Acquisition Expands High-Speed Internet, Voice, and Technology Services for Local BusinessesPollock Company Logo AUGUSTA, Ga., Dec. 14, 2025 (GLOBE NEWSWIRE) — Pollock Company, a third-generation, family-owned leader in office technology, managed IT services, and physical security solutions for more than 60 years, proudly announces the acquisition of ATG Communications, a respected local Internet and Voice Service Provider serving the community for 36 years. This strategic acquisition represents a major investment in the local community and a key step forward in Pollock Company’s mission to deliver comprehensive, end-to-end technology solutions. By integrating ATG Communications’ reliable internet and voice infrastructure with Pollock Company’s broad portfolio — including managed IT, cybersecurity, print solutions, workflow optimization,...

Continue reading

Mission Success: Rocket Lab Deploys First Dedicated Launch for Japan Aerospace Exploration Agency (JAXA)

Written by Customer Service on . Posted in Public Companies.

MAHIA, New Zealand, Dec. 13, 2025 (GLOBE NEWSWIRE) — Rocket Lab Corporation (Nasdaq: RKLB) (“Rocket Lab” or “the Company”), a global leader in launch services and space systems, today successfully launched its first dedicated mission for the Japan Aerospace Exploration Agency (JAXA) – a pivotal marker of Electron’s global importance for regular, reliable, and dedicated access to space. The “RAISE And Shine” mission lifted off from Rocket Lab Launch Complex 1 in New Zealand on December 14, 2025 at 03:09 UTC / 16:09 NZDT to successfully deploy the agency’s RApid Innovative payload demonstration SatellitE-4 (RAISE-4) spacecraft: a demonstration of eight technologies developed by private companies, universities, and research institutions throughout Japan. The mission was the first of two dedicated missions for JAXA’s Innovative Satellite...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.